Wayu-B (02256) announced that Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical), a subsidiary of the company, announced that it will release the first human clinical study data on its next-generation FGFR2/3 highly selective inhibitor ABSK061 in the form of an oral report at the 2024 European Society of Oncology Targeted Anti-cancer Treatment Conference (ESMO Targeted Cancer Treatment Conference, “ESMO TAT”).
As the world's first selective FGFR2/3 inhibitor to enter clinical trials, ABSK061 showed significant improvements in side effects such as hyperphosphatemia compared to previous pan-FGFR inhibitors in dose climbing tests for patients with advanced solid tumors. Many patients with lung cancer, stomach cancer, etc. containing changes in the FGFR gene respond. This result also lays a good foundation for future development of ABSK061 in other diseases such as achondroplasia.